These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29339046)

  • 1. Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?
    Gonzalez-Motta A; Roach M
    Pract Radiat Oncol; 2018; 8(3):185-202. PubMed ID: 29339046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
    Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
    Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
    Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is robotic arm stereotactic body radiation therapy “virtual high dose ratebrachytherapy” for prostate cancer? An analysis of comparative effectiveness using published data [corrected].
    Zaorsky NG; Hurwitz MD; Dicker AP; Showalter TN; Den RB
    Expert Rev Med Devices; 2015 May; 12(3):317-27. PubMed ID: 25540018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.
    Jackson WC; Silva J; Hartman HE; Dess RT; Kishan AU; Beeler WH; Gharzai LA; Jaworski EM; Mehra R; Hearn JWD; Morgan TM; Salami SS; Cooperberg MR; Mahal BA; Soni PD; Kaffenberger S; Nguyen PL; Desai N; Feng FY; Zumsteg ZS; Spratt DE
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):778-789. PubMed ID: 30959121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer.
    Shaverdian N; Verruttipong D; Wang PC; Kishan AU; Demanes DJ; McCloskey S; Kupelian P; Steinberg ML; King CR
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):516-525. PubMed ID: 28126301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review.
    Foerster R; Zwahlen DR; Buchali A; Tang H; Schroeder C; Windisch P; Vu E; Akbaba S; Bostel T; Sprave T; Zamboglou C; Zilli T; Stelmes JJ; Telkhade T; Murthy V
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33673077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
    Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
    Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.
    Zhang B; Leech M
    Anticancer Res; 2020 May; 40(5):2419-2428. PubMed ID: 32366385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer.
    Spratt DE; Scala LM; Folkert M; Voros L; Cohen GN; Happersett L; Katsoulakis E; Zelefsky MJ; Kollmeier MA; Yamada Y
    Brachytherapy; 2013; 12(5):428-33. PubMed ID: 23622710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.
    Zaorsky NG; Den RB; Doyle LA; Dicker AP; Hurwitz MD
    Expert Rev Med Devices; 2013 Nov; 10(6):751-63. PubMed ID: 24195459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy.
    Chen WC; Tokita KM; Ravera J; Fu P; Jiang Y; Kaminsky DA; Ponsky L; Ellis RJ
    Brachytherapy; 2013; 12(5):422-7. PubMed ID: 23380382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic Body Radiation Therapy for Patients with Early-stage Prostate Cancer.
    Linney H; Barrett S
    Anticancer Res; 2018 Mar; 38(3):1231-1240. PubMed ID: 29491045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series.
    Wilcox SW; Aherne NJ; McLachlan CS; McKay MJ; Last AJ; Shakespeare TP
    J Med Imaging Radiat Oncol; 2015 Feb; 59(1):125-33. PubMed ID: 25588566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.
    Anwar M; Weinberg V; Seymour Z; Hsu IJ; Roach M; Gottschalk AR
    Radiat Oncol; 2016 Jan; 11():8. PubMed ID: 26792201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
    Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
    Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
    Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
    Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.